Want to see PMVP full AI Analyst Report?
PMVP Stock Chart & Stats
$1.12
-$0.01(-0.65%)
At close: 4:00 PM EST
$1.12
-$0.01(-0.65%)
Day’s Range― - ―
52-Week Range$1.02 - $1.88
Previous CloseN/A
Volume81.53K
Average Volume (3M)311.29K
Market Cap
$71.46M
Enterprise Value-$27.12
Total Cash (Recent Filing)$93.55M
Total Debt (Recent Filing)$293.00K
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Aug 06, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.49
Shares Outstanding53,331,764
10 Day Avg. Volume386,512
30 Day Avg. Volume311,293
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.63
Price to Sales (P/S)0.00
P/FCF Ratio-0.89
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$4.00Price Target Upside257.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.46
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet And Strategic InterestA cash balance sufficient to fund operations into 2027, coupled with noted interest from potential buyers, reduces near-term financing pressure and increases takeover appeal.
Clinical EfficacyPYNNACLE trial results showing a 46% overall response rate and durable responses support the drug's potential to meet efficacy expectations for regulators and acquirers.
Safety ProfileA low treatment discontinuation rate of 4% for drug-related adverse events indicates a manageable safety profile that could ease regulatory review and commercial adoption.
Bears Say
Development Timeline RiskNegative clinical data or delays in advancing candidates into later-stage trials could push back commercialization timelines and depress the stock.
Dilution And Commercial ExecutionNeed for additional capital or lower-than-expected commercial uptake could lead to share dilution and weaker revenue delivery per share.
Regulatory Approval RiskFailure to obtain regulatory approval for the lead candidate would sharply reduce projected revenues and investor confidence.
PMV Pharmaceuticals News
PMVP FAQ
What was Pmv Pharmaceuticals, Inc.’s price range in the past 12 months?
Pmv Pharmaceuticals, Inc. lowest stock price was $1.02 and its highest was $1.88 in the past 12 months.
What is Pmv Pharmaceuticals, Inc.’s market cap?
Pmv Pharmaceuticals, Inc.’s market cap is $71.46M.
When is Pmv Pharmaceuticals, Inc.’s upcoming earnings report date?
Pmv Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 16 days.
How were Pmv Pharmaceuticals, Inc.’s earnings last quarter?
Pmv Pharmaceuticals, Inc. released its earnings results on May 12, 2026. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.41 by $0.07.
Is Pmv Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Pmv Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Pmv Pharmaceuticals, Inc. pay dividends?
Pmv Pharmaceuticals, Inc. does not currently pay dividends.
What is Pmv Pharmaceuticals, Inc.’s EPS estimate?
Pmv Pharmaceuticals, Inc.’s EPS estimate is -0.39.
How many shares outstanding does Pmv Pharmaceuticals, Inc. have?
Pmv Pharmaceuticals, Inc. has 53,331,764 shares outstanding.
What happened to Pmv Pharmaceuticals, Inc.’s price movement after its last earnings report?
Pmv Pharmaceuticals, Inc. reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.41. Following the earnings report the stock price went up 2.158%.
Which hedge fund is a major shareholder of Pmv Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in PMVP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PMV Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.00 (257.14% Upside)
$4.00 (257.14% Upside)
Blogger Sentiment
Bearish
PMVP Sentiment 70%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-43.40%
Trailing 12-Months
Company Description
Pmv Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.
PMVP Stock 12 Month Forecast
Average Price Target
$4.00
▲(257.14% Upside)
Technical Analysis
X4 Pharmaceuticals
―
ABVC BioPharma
―
Prelude Therapeutics
―
Gain Therapeutics
―
Immix Biopharma
―
Ownership Overview
12.70% Insiders
7.84% Mutual Funds
0.68% Other Institutional Investors
74.84% Public Companies and
Individual Investors